Sep 17, 2018 FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma Learn More
Aug 29, 2018 Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference Learn More
Aug 20, 2018 Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma Patients Learn More
Aug 13, 2018 Cellectar’s CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing’s Sarcoma Learn More